Fertilist IVF Center
Menu

Fertilist Privacy Notice on the Protection and Processing of Personal Data

Data Controller

Your personal data may be processed within the scope described below by Momentum Sağlık ve Turizm ve Catering Hizmetleri ve Ticaret Anonim Şirketi (the “Company”), acting as the data controller pursuant to Personal Data Protection Law No. 6698 (the “Law”).

Purposes and Legal Grounds for Processing Personal Data

The personal data collected may be processed by our business units for the purposes listed below (the “Purposes”), within the scope of carrying out the work required to provide you with the products and services offered by our Company and conducting the related business processes, and in accordance with the personal data processing conditions set out in Articles 5 and 6 of the Law.

Your personal data is processed for the following purposes on the legal ground under Article 5/2(c) of the Law, where processing is directly related to the establishment or performance of a contract, provided that it is necessary for the processing of the personal data of the parties to the contract:

  • Contacting you through the completion of the website contact form,
  • Carrying out informational activities about products and services,
  • Carrying out the processes related to the provision and performance of products and services,
  • Carrying out appointment processes,
  • Carrying out product and service sales processes,
  • Carrying out contract processes,
  • Receiving and evaluating requests and complaints,
  • Carrying out communication activities.

Your personal data is processed for the following purposes on the legal ground under Article 5/2(f) of the Law, where processing is necessary for the Company’s legitimate interests:

  • Carrying out service production and operation processes,
  • Planning and executing customer relationship management processes,
  • Carrying out information security processes,
  • Carrying out communication activities,
  • Carrying out audit and ethics activities,
  • Carrying out / auditing business activities,
  • Planning and executing internal processes of the Company,
  • Contacting you to receive and evaluate feedback regarding the products and services offered by the Company,
  • Conducting the analyses necessary to improve our services.

Your personal data is processed for the following purposes on the legal ground under Article 5/2(ç) of the Law, relating to the Company’s legal obligations:

  • Receiving and evaluating requests and complaints,
  • Following up and conducting legal affairs,
  • Carrying out accounting and finance processes,
  • Conducting activities in compliance with legislation,
  • Carrying out retention and archiving activities,
  • Fulfilling requests from official authorities.

Where you share your health data with us within the scope of appointment processes, such data will be processed by persons under a duty of confidentiality pursuant to Article 6/3 of the Law, for the purposes of medical diagnosis, treatment and care services, and the planning and management of healthcare services. In addition, health data you share may be processed on the legal ground of being expressly provided for by law under Article 6/2(b) of the Law and transferred pursuant to Article 8/3 of the Law, in the event of requests from courts and other competent authorities and institutions.

Based on your explicit consent: processing of your identity, contact, transaction and marketing information for the purpose of conducting satisfaction surveys and related communications through surveys and similar methods, promoting our products or services, providing information about openings, invitations or events, and sending commercial electronic messages to your contact information, including the distribution of newsletters.

To Whom and for What Purpose Processed Personal Data May Be Transferred

Your personal data collected may be transferred, in line with the Purposes, to our suppliers, to public institutions authorized by law, and to private persons authorized by law, in accordance with the personal data processing conditions set out in Article 5 of the Law and the rules on the transfer of personal data set out in Article 8 of the Law.

Limited to the purposes of carrying out the processes related to the provision and performance of products and services and enabling your appointment to be created, your personal data may be transferred to the affiliated IVF center you have requested, on the legal grounds under Article 5/2(c) of the Law, where processing is directly related to the establishment or performance of a contract, provided that it is necessary for the processing of the personal data of the parties to the contract, and under Article 5/2(f) of the Law, where processing is necessary for the Company’s legitimate interests; your health data may be transferred by persons under a duty of confidentiality or by competent authorities and institutions, where necessary for the protection of public health, preventive medicine, medical diagnosis, treatment and care services, and the planning, management and financing of healthcare services.

Method of Collecting Personal Data

Your personal data is collected by the Company, within the scope of realizing the Purposes, through electronic means including our websites, our contact form, our mobile application, our Call Center, our web application, our integrated operating systems, the portal(s) through which online services are provided, and e-mail channels, and through physical means such as courier/mail, fax, and face-to-face meetings. Your personal data is processed on the legal grounds set out above, in accordance with the personal data processing conditions specified in Articles 5 and 6 of the Law.

Rights of the Data Subject under Article 11 of the Law

As a data subject, we would like to inform you that you have the following rights pursuant to Article 11 of the Law:

  • To learn whether your personal data is being processed,
  • To request information if your personal data has been processed,
  • To learn the purpose of processing your personal data and whether it is used in accordance with that purpose,
  • To know the third parties to whom your personal data is transferred, domestically or abroad,
  • To request the correction of your personal data if it has been processed incompletely or incorrectly, and to request that this correction be notified to third parties to whom your personal data has been transferred,
  • To request the deletion or destruction of your personal data if the reasons requiring its processing no longer exist, even though it has been processed in accordance with the Law and other relevant laws, and to request that this be notified to third parties to whom your personal data has been transferred,
  • To object to a result that is to your detriment arising from the analysis of your processed data exclusively through automated systems,
  • To request compensation for damages in the event you suffer harm due to the unlawful processing of your personal data.

You may submit requests regarding the rights listed above to our Company in accordance with applicable legislation. You may submit your request through the contact information provided below. Depending on the nature of your request, it will be concluded free of charge as soon as possible and within thirty days at the latest; however, if the process requires an additional cost, a fee may be charged in accordance with the tariff determined by the Personal Data Protection Board.

Application Methods

Application MethodAddress to Apply To
1. Written Application
In person with a wet-ink signature, through a notary public, or by courier/mail		Güzelbahçe Sok. No: 20, Postal code: 34365, Nişantaşı, Istanbul, Türkiye
2. Via Registered Electronic Mail (KEP)
Using a registered electronic mail (KEP) address		momentum.osgb@hs02.kep.tr
3. Via E-mail Address
Using the e-mail address below		kisiselveri@kocsaglikyanimda.com

The IVF Process

IVF treatment consists of four stages. These stages can be listed as follows: 1. Assessment of the couple, examination, diagnostic tests and determination of the treatment protocol: During the assessment of the couple, the patient's symptoms, medical history and family history are reviewed, and factors related to the cause of infertility are investigated. An ultrasound scan is performed to examine the structure of the reproductive organs, the uterus and the ovaries, and to identify any diseases or changes in neighbouring organs, investigating their relationship to infertility. If a problem is identified that hinders treatment or reduces the chances of success, steps are taken to resolve this issue first. During the ultrasound scan, an assessment of 'ovarian reserve' is carried out, which plays a significant role in selecting the treatment to be administered in the future and in determining the likelihood of treatment success. In addition, with a view to preparing for pregnancy, the presence of certain hormonal, metabolic and viral diseases that could adversely affect pregnancy, as well as the patient's immune status, is investigated. 2. Stimulation of the ovaries with medication: This constitutes the most important stage of the treatment. The treatment regimen to be administered during ovarian stimulation is determined based on the patient's age, the appearance of the ovaries on ultrasound, hormone test results, and, in patients who have previously undergone IVF, the response to treatment in the previous cycle. The physician's experience in determining this treatment directly influences the outcome. 3. Egg retrieval: Under anaesthesia, guided by transvaginal ultrasound, eggs are aspirated from the follicles containing the egg cells using a fine needle and removed from the body. 4. Embryo transfer: The best 1 or 2 embryos (fertilised eggs) are selected from those monitored in the laboratory and transferred into the uterus using a thin catheter. This procedure is similar to a routine examination and does not require anaesthesia.

The ideal time to start the egg stimulation process in IVF treatment is on the second or third day of the period. However, this is not an absolute requirement. Under certain specific conditions, ovarian stimulation medication can be started at any stage of the menstrual cycle.

Ovarian stimulation typically lasts approximately 8 to 14 days, although in some cases it may be shorter or longer. The growth of follicles that may contain eggs is monitored via ultrasound. Monitoring will require 4-5 visits to the IVF clinic during the course of treatment. In addition to ultrasound scans, hormone monitoring may also be carried out in some women. These hormones include oestrogen, progesterone and LH, and in some cases FSH. Once the follicles have reached the desired size, maturation injections (known as HCG or GnRH analogues) are administered to bring the eggs inside them to full maturity, and, barring certain special circumstances, the oocyte pick-up procedure is usually performed 34-38 hours later.

The oocyte pick-up (OPU) procedure is usually performed under local anaesthesia and takes approximately 15-30 minutes, depending on the number of follicles. If the ovarian response is limited and a small number of eggs are anticipated, the procedure may also be performed under local anaesthesia whilst the patient is awake. Following the procedure, you can return home after approximately 1-2 hours of observation and monitoring.

Once the oocyte pick-up has been completed, fertilisation with sperm takes place. The embryos are then monitored in the laboratory in special culture media for 3-5 days, or in some cases for 6-7 days. If there are any remaining high-quality embryos suitable for freezing after the transfer of those assessed in the laboratory and selected for transfer, these can be frozen and stored for transfer at a later date.

In Türkiye, the number of embryos that can be transferred is determined by regulations; for women under 35, it is limited to 1 embryo for the first 2 attempts, and for women over 35, it is limited to a maximum of 2 embryos. Under no circumstances is the transfer of more than two embryos permitted.

During the IVF treatment, ultrasound scans and blood tests are carried out during the egg stimulation phase to monitor egg development and adjust the dosage. On average, you will need to visit the hospital four or five times during the treatment process for these check-ups. As the time spent at the hospital during these check-ups is brief, they can be carried out without disrupting daily life or work routines.

Success Rates

The most up-to-date measure of success is the live birth rate of a single healthy baby per IVF cycle initiated. Multiple pregnancies are now considered high-risk, and transferring embryos one at a time wherever possible has become a global trend.

There are many variables that determine the chances of success in IVF, but the most important of these are the woman's age and ovarian reserve. In younger women with high ovarian reserve, the pregnancy rate (defined as the proportion of pregnancies resulting in live birth following the sequential transfer of all embryos obtained from a single egg retrieval) is higher. However, in women over the age of 40, this rate decreases, and by the age of 45, it drops to very low levels. Unfortunately, these results are not altered by supplements or 'rejuvenating' agents administered to the ovaries. AMH is one of the most reliable markers of ovarian reserve. Although a low AMH level does not necessarily mean pregnancy will or will not occur, it indicates that the number of oocytes picked up during the oocyte pick-up procedure will be low. Sperm quality is also a factor that directly affects embryo quality and the chances of pregnancy. In cases where there are very few sperm in the semen or where sperm must be retrieved from the testicles, embryo development is adversely affected.

Ovarian reserve is determined by an experienced physician performing a transvaginal ultrasound scan to assess the number of antral follicles present in the ovaries and their distribution. With advancing age, there will be a loss in the ovarian reserve; concurrently, there will be a reduction in ovarian volume and a decrease in the number of antral follicles. In addition to ultrasound, anti-Müllerian hormone (AMH) is the marker that best reflects ovarian reserve. Low AMH levels allow us to predict that the response from the ovaries during treatment will be poor, enabling us to tailor the treatment protocol accordingly.

In patients who have previously undergone unsuccessful IVF attempts, the most important factor determining the chances of success in the next treatment is the information regarding the ovarian response and embryo quality from the first treatment. When planning a new treatment, data from the previous treatment cycle is taken into account to plan how to obtain the healthiest and highest number of eggs from the ovaries. A history of low oocyte pick-up or poor-quality embryo development may be due to factors related to the patient, or it may be linked to the treatment protocol and medication doses used, as well as laboratory conditions. Other reasons for failure to achieve success include fibroids, polyps, blocked fallopian tubes, uterine malformations and intrauterine adhesions. Correcting these issues, where applicable, will increase the chances of pregnancy. Additional tests and assessments, such as investigations into coagulation disorders (congenital or acquired) and immune function, are not routinely recommended. The cause-and-effect relationship for both is unclear.

Various supportive medications, primarily the hormone progesterone, are used to support the embryo's implantation in the uterus following embryo transfer. The use of medications without scientific evidence (such as aspirin, blood thinners, agents that inhibit uterine contractions, immunosuppressive drugs, etc.) or strict bed rest will not increase the embryo's chances of implantation and will only cause unnecessary anxiety and expense.

Cost and SGK Support

In IVF treatment, state funding can be obtained by producing an IVF report (signed by three people). To obtain this report, you must apply to centers authorised to issue such reports. Your physician must determine that IVF is necessary for the report to be issued. To obtain the report, one of the spouses must have at least 5 years of service with the Social Security Institution and a minimum of 900 days of contribution days, and the female partner must undergo a medical examination confirming she has no medical conditions preventing pregnancy. If deemed appropriate, an SGK report may then be issued.

Here, the couple's medical history and current condition regarding IVF treatment are significant. Following the physician's assessment, different methods to increase the chances of pregnancy or mandatory procedures to achieve pregnancy may be required. Services can be categorised as those related to laboratory and embryology, genetic and advanced diagnostic services, freezing and storage services, and services related to uterine preparation. These procedures include Embryo Glue, the microchip technique, IMSI, genetic embryo biopsy, and hysteroscopy/hysteroscopic polyp removal.

View All Questions